Securities Code: 002393 Securities Abbreviation: Life Science Pharmaceutical Announcement No.: 2026-016
Tianjin Life Science Pharmaceutical Co., Ltd. Announcement on the Forecast of Routine Related Transactions for 2026
The Company and all members of its board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.
Key Information Prompt: Tianjin Life Science Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "this Company") and its wholly-owned and controlled subsidiaries are expected to conduct routine related transactions with related parties totaling no more than RMB 850 million in 2026. The Company's independent directors' special committee has reviewed the above related transactions and issued an opinion. Related directors abstained from voting, and the non-related directors unanimously approved this proposal.
I. Basic Situation of Routine Related Transactions
(I) Review Procedures for Routine Related Transactions
- On March 19, 2025, the Company held the 50th meeting of the Seventh Board of Directors, which reviewed and approved the "Proposal on the Forecast of Routine Related Transactions for the Company in 2025." In 2025, the total estimated routine related transactions between the Company and its subsidiaries and related parties did not exceed RMB 700 million. The actual total amount of routine related transactions completed by the Company in 2025 was RMB 16,878.12 million, which did not exceed the estimated amount.
- On March 24, 2026, the Company held the 4th meeting of the Eighth Board of Directors, which reviewed and approved the "Proposal on the Forecast of Routine Related Transactions for the Company in 2026." Related directors Mr. Teng Fei, Ms. Duan Shuang, and Ms. Lu Xiaoman abstained from voting. This proposal was approved with 6 votes in favor, 0 votes against, and 0 abstentions.
- The Company estimates that the total amount of routine related transactions in 2026 will reach the threshold requiring approval by the shareholders' meeting as stipulated by the "Shenzhen Stock Exchange Stock Listing Rules" and the Company's "Management Measures for Related Transaction Decision-Making" (revised in January 2026). Therefore, it needs to be submitted for approval by the shareholders' meeting.
(II) Categories and Amounts of Estimated Related Transactions for 2026